- Home
- NPV vs CUE Comparison
NPV vs CUE Comparison
Compare NPV & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPV | CUE |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 177.0M |
| IPO Year | 1995 | 2017 |
Fundamental Metrics
Financial Performance| Metric | NPV | CUE |
|---|---|---|
| Price | $9.72 | $18.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 126.8K | ★ 127.3K |
| Earning Date | 01-01-0001 | 11-24-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $9.05 | $0.17 |
| 52 Week High | $11.81 | $45.50 |
Technical Indicators
Market Signals| Indicator | NPV | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 42.87 |
| Support Level | $9.05 | $17.00 |
| Resistance Level | $11.61 | $22.49 |
| Average True Range (ATR) | 0.16 | 1.96 |
| MACD | 0.00 | 0.24 |
| Stochastic Oscillator | 20.41 | 28.64 |
Price Performance
Historical ComparisonAbout NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. The company mostly invests in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities, Housing/Multifamily, Transportation, and Others.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.